###begin article-title 0
###xml 63 68 <span type="species:ncbi:9606">Human</span>
Interfering Residues Narrow the Spectrum of MLV Restriction by Human TRIM5alpha
###end article-title 0
###begin p 1
###xml 291 294 283 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 123 144 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 146 149 <span type="species:ncbi:11786">MLV</span>
###xml 231 234 <span type="species:ncbi:11786">MLV</span>
###xml 298 303 <span type="species:ncbi:9606">human</span>
###xml 408 411 <span type="species:ncbi:11786">MLV</span>
###xml 441 444 <span type="species:ncbi:11786">MLV</span>
###xml 492 495 <span type="species:ncbi:11786">MLV</span>
TRIM5alpha is a restriction factor that limits infection of human cells by so-called N- but not B- or NB-tropic strains of murine leukemia virus (MLV). Here, we performed a mutation-based functional analysis of TRIM5alpha-mediated MLV restriction. Our results reveal that changes at tyrosine336 of human TRIM5alpha, within the variable region 1 of its C-terminal PRYSPRY domain, can expand its activity to B-MLV and to the NB-tropic Moloney MLV. Conversely, we demonstrate that the escape of MLV from restriction by wild-type or mutant forms of huTRIM5alpha can be achieved through interdependent changes at positions 82, 109, 110, and 117 of the viral capsid. Together, our results support a model in which TRIM5alpha-mediated retroviral restriction results from the direct binding of the antiviral PRYSPRY domain to the viral capsid, and can be prevented by interferences exerted by critical residues on either one of these two partners.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 314 319 <span type="species:ncbi:9606">Human</span>
###xml 370 391 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 393 396 <span type="species:ncbi:11786">MLV</span>
###xml 631 634 <span type="species:ncbi:11786">MLV</span>
###xml 683 686 <span type="species:ncbi:11786">MLV</span>
Mammalian cells are endowed with intrinsic lines of defence against retroviruses, which notably contribute to limiting the cross-species transmission of these pathogens. TRIM5alpha is one such restriction factor, which acts by recognizing the capsid of incoming retroviruses through its C-terminal PRYSPRY domain. Human TRIM5alpha potently blocks the so-called N-tropic murine leukemia virus (MLV), but is ineffective against the closely related B-tropic and Moloney strains. In this study, we demonstrate that substitution of a single amino acid in the PRYSPRY domain of this protein expands its antiviral activity to these other MLV strains. Conversely, we show that protection of MLV from this restriction is governed by the negative influence of specific residues at a few critical positions of the retroviral capsid. These results support the model of a direct interaction between TRIM5alpha and retroviral capsids, shedding light on an important arm of innate antiretroviral immunity.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 526 527 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b001">1</xref>
Retroelements constitute important evolutionary forces for the genome of higher organisms, yet their uncontrolled spread, whether from endogenous loci or within the context of retroviral infections, can cause diseases such as cancer, autoimmunity and immunodeficiency, including AIDS. Correspondingly, a variety of host-encoded activities limit this process, behaving as the arms of a line of defence commonly called intrinsic immunity, which notably contributes to restricting the cross-species transmission of retroviruses [1].
###end p 6
###begin p 7
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fv1</italic>
###xml 94 97 94 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag</italic>
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b002">2</xref>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b003">3</xref>
###xml 356 357 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 365 366 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 377 380 377 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fv1</italic>
###xml 636 637 636 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b004">4</xref>
###xml 638 639 638 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b005">5</xref>
###xml 719 720 719 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
###xml 728 729 728 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 175 180 <span type="species:ncbi:10090">mouse</span>
###xml 192 213 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 215 218 <span type="species:ncbi:11786">MLV</span>
###xml 249 252 <span type="species:ncbi:11786">MLV</span>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
###xml 471 474 <span type="species:ncbi:11786">MLV</span>
###xml 587 590 <span type="species:ncbi:11786">MLV</span>
###xml 650 653 <span type="species:ncbi:11786">MLV</span>
###xml 658 661 <span type="species:ncbi:11786">MLV</span>
The product of the Friend virus susceptibility 1 (Fv1) gene, which shares similarity with the gag region of an endogenous retrovirus, conditions the susceptibility of various mouse strains to murine leukemia virus (MLV) [2,3]. N-tropic and B-tropic MLV strains replicate in Swiss/NIH and in Balb/c mice, respectively, reflecting the presence of either the n or the b allele of Fv1 in the genome of these animals. A critical determinant of the differential sensitivity of MLV strains to Fv1 lies in amino acid 110 of the viral capsid (CA), which is an arginine in the prototypic N-tropic MLV and a glutamate in its B-tropic counterpart [4,5]. Moloney MLV (Mo-MLV) harbors an alanine at this position and escapes both Fv1n and Fv1b, hence is termed NB-tropic.
###end p 7
###begin p 8
###xml 223 224 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b006">6</xref>
###xml 225 227 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b010">10</xref>
###xml 546 549 538 541 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mac</sub>
###xml 593 595 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b011">11</xref>
###xml 596 598 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b013">13</xref>
###xml 684 687 668 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mac</sub>
###xml 699 700 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b006">6</xref>
###xml 701 702 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b009">9</xref>
###xml 703 705 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b011">11</xref>
###xml 706 708 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b014">14</xref>
###xml 2 5 <span type="species:ncbi:11786">MLV</span>
###xml 36 42 <span type="species:ncbi:10090">murine</span>
###xml 73 78 <span type="species:ncbi:9606">human</span>
###xml 392 427 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 429 434 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 442 445 <span type="species:ncbi:11786">MLV</span>
###xml 500 529 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 574 577 <span type="species:ncbi:11786">MLV</span>
###xml 586 591 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 601 606 <span type="species:ncbi:9606">Human</span>
###xml 642 645 <span type="species:ncbi:11786">MLV</span>
###xml 692 697 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
N-MLV is restricted too in some non-murine mammalian cells, including of human origin, which do not encode Fv1. Blockade is in these cases mediated by TRIM5alpha, a member of the tripartite motif (TRIM) family of proteins [6-10]. TRIM5alpha also prevents the cross-species transmission of primate lentiviruses. The orthologues present in Old World monkeys, including macaque rhesus, restrict human immunodeficiency virus type 1 (HIV-1) and N-MLV, while those from New World monkeys, tend to restrict simian immunodeficiency virus of macaques (SIVmac) and for some species N-MLV but not HIV-1 [11-13]. Human TRIM5alpha (huTRIM5alpha) blocks N-MLV, but is only weakly active against SIVmac and HIV-1 [6-9,11,14].
###end p 8
###begin p 9
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b010">10</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b015">15</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b016">16</xref>
###xml 279 281 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b017">17</xref>
###xml 282 284 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b019">19</xref>
###xml 554 556 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b012">12</xref>
###xml 557 559 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b020">20</xref>
###xml 560 562 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b023">23</xref>
###xml 670 672 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b011">11</xref>
###xml 927 929 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b011">11</xref>
###xml 930 932 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b024">24</xref>
###xml 933 935 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b025">25</xref>
###xml 1125 1127 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b026">26</xref>
###xml 920 925 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1025 1038 <span type="species:ncbi:9544">rhesus monkey</span>
###xml 1080 1083 <span type="species:ncbi:11786">MLV</span>
All TRIM proteins contain a RING, a B-Box and a coiled-coil region, which together constitute the so-called RBCC domain [10,15,16]. TRIM5alpha further harbors at its C-terminus the PRYSPRY or B30.2 domain, responsible for the viral capsid-specific capture of restricted viruses [17-19]. Sequence alignments of the PRYSPRY domains of various primate TRIM5alpha and other related TRIM proteins reveal 4 variable regions (V1, V2, V3 and V4), predicted to constitute surface-exposed loops based on the structure of the homologous domain of related proteins [12,20-23]. While V1, V2 and V3 were all found to contribute to the antiviral specificity of TRIM5alpha orthologues [11], V1 was shown to play a most critical role in this process. Within this loop, removing a positive charge at position 332 or substituting residues 335 to 340 by an eight amino acid rhesus sequence confers huTRIM5alpha with the ability to restrict HIV-1 [11,24,25]. Conversely, introducing residues 335-340 of huTRIM5alpha at the corresponding locus of rhesus monkey TRIM5alpha (rhTRIM5alpha) enhances the N-MLV blocking activity of the simian protein [26].
###end p 9
###begin p 10
###xml 167 170 <span type="species:ncbi:11786">MLV</span>
###xml 181 184 <span type="species:ncbi:11786">MLV</span>
###xml 191 194 <span type="species:ncbi:11786">MLV</span>
###xml 270 273 <span type="species:ncbi:11786">MLV</span>
The present study was designed to define further how TRIM5alpha recognizes retroviral capsids. Our results indicate that, if huTRIM5alpha efficiently restricts only N-MLV and not B-MLV or Mo-MLV, this is due to the negative influence of a key residue in V1. Conversely, MLV is capable of avoiding restriction via the interdependent influences of a cluster of amino acids exposed at the surface of its capsid.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 98 101 <span type="species:ncbi:11786">MLV</span>
A Single Amino Acid Substitution in huTRIM5alpha PRYSPRY Domain Extends Its Activity to B- and Mo-MLV
###end title 12
###begin p 13
###xml 289 292 285 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fv1</italic>
###xml 298 307 294 303 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Mus dunni</named-content>
###xml 334 342 330 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g001">Figure 1</xref>
###xml 641 650 633 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g001">Figures 1</xref>
###xml 656 657 648 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g002">2</xref>
###xml 771 774 763 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">339</sup>
###xml 814 817 806 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">339</sup>
###xml 878 881 870 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 298 307 <span type="species:ncbi:254704">Mus dunni</span>
###xml 495 498 <span type="species:ncbi:11786">MLV</span>
###xml 503 506 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 709 712 <span type="species:ncbi:11786">MLV</span>
###xml 795 800 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 944 947 <span type="species:ncbi:11786">MLV</span>
###xml 975 978 <span type="species:ncbi:11786">MLV</span>
In order to characterize the interaction between huTRIM5alpha and its viral targets, we introduced amino acid changes in the central V1 region of its PRYSPRY domain. Cell lines stably expressing the resulting mutants were generated by retroviral vector-mediated transduction of permissive Fv1-null Mus dunni tail fibroblasts (MDTFs) (Figure 1). A first series of MDTF derivatives expressing huTRIM5alpha mutants carrying single alanine substitutions at positions 334 to 339 were challenged with MLV- or HIV-derived green fluorescent protein (GFP)-expressing vectors, scoring infection by fluorescence-activated cell sorting (FACS) analysis (Figures 1A and 2A). All mutants conserved the ability to restrict N-MLV, albeit at a slightly reduced efficiency for some (e.g., F339A). None could block HIV-1, except for F339A that was lowly active. In contrast, replacement of tyrosine336 by alanine yielded a mutant capable of efficiently blocking B-MLV and, to a small extent, Mo-MLV.
###end p 13
###begin title 14
Stable Expression of Wild-Type or PRYSPRY V1 Mutant Forms of huTRIM5alpha
###end title 14
###begin p 15
(A) Schematic representation of the domains present in huTRIM5alpha. Numbers refer to the amino acid position. V1 through V4 designate the four variable regions found in the PRYSPRY domain. The V1 amino acid sequence is shown below, with mutated amino acids (334 to 339) indicated with an asterisk (*). Below is a western blot analysis of extracts from MDTF cells stably transduced with retroviral vectors expressing HA-tagged versions of these huTRIM5alpha derivatives, using HA (top) and PCNA (bottom)-specific antibodies.
###end p 15
###begin p 16
(B) Same analysis, with derivatives carrying the indicated amino acid substitutions or a deletion (Delta) at position 336.
###end p 16
###begin title 17
###xml 12 13 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 16 17 12 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 36 39 <span type="species:ncbi:11786">MLV</span>
HuTRIM5alphaY336A Potently Blocks B-MLV at an Early Stage of Infection
###end title 17
###begin p 18
###xml 426 427 418 419 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 430 431 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 178 181 <span type="species:ncbi:11786">MLV</span>
###xml 191 196 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) MDTF cells expressing wild-type (WT) or indicated mutant forms of huTRIM5alpha, or transduced with a control vector (vector), were challenged with serial 2-fold dilutions of MLV-based or HIV-1-based GFP vectors initially titered on permissive MDTF cells. Infections were scored at 48 hours post-infection by FACS. Curves are representatives of at least two independent experiments, and phenotype observed with huTRIM5alphaY336A was confirmed in three independently obtained stable cell lines.
###end p 18
###begin p 19
###xml 35 38 35 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 485 486 481 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 512 513 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 138 141 <span type="species:ncbi:11786">MLV</span>
###xml 576 581 <span type="species:ncbi:10090">mouse</span>
(B) Cells expressing wild-type or Y336A mutated huTRIM5alpha, or control cells (vector), were challenged with equal doses of N-, B- or Mo-MLV. Cellular DNA extractions were performed before (0 h) or 6 h, 8 h or 5 days post-infection. Intermediate minus strand DNA reverse transcription products were amplified by PCR. For each cell line, transduction was performed in triplicate in the absence (1, 2) or presence (-) of azidothymidine (AZT), a reverse transcription inhibitor. Water (C-) and the plasmid pCNCG (C+) were used as negative and positive controls for the PCR. The mouse peripheral myelin protein (Pmp22) gene was used as a loading control.
###end p 19
###begin p 20
(C) In parallel of the experiment described in (B), the percentage of GFP-positive cells was determined 5 days post-infection by flow cytometry.
###end p 20
###begin p 21
###xml 245 246 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b007">7</xref>
###xml 247 249 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b013">13</xref>
###xml 250 252 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b027">27</xref>
###xml 348 349 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
###xml 430 432 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b028">28</xref>
###xml 433 435 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b029">29</xref>
###xml 503 506 495 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 715 723 703 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g002">Figure 2</xref>
###xml 1115 1116 1095 1096 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 1119 1120 1099 1100 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 1537 1545 1513 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g002">Figure 2</xref>
###xml 1551 1552 1527 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g002">2</xref>
###xml 1619 1620 1591 1592 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 1623 1624 1595 1596 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 30 33 <span type="species:ncbi:11786">MLV</span>
###xml 149 152 <span type="species:ncbi:11786">MLV</span>
###xml 326 329 <span type="species:ncbi:11786">MLV</span>
###xml 573 576 <span type="species:ncbi:11786">MLV</span>
###xml 872 875 <span type="species:ncbi:11786">MLV</span>
###xml 967 970 <span type="species:ncbi:11786">MLV</span>
###xml 1019 1022 <span type="species:ncbi:11786">MLV</span>
###xml 1130 1133 <span type="species:ncbi:11786">MLV</span>
We examined the step of the B-MLV replicative cycle targeted by this expanded-spectrum huTRIM5alpha mutant. Several reports have demonstrated that N-MLV blockade by huTRIM5alpha occurs at an early post-entry stage, before reverse transcription [7,13,27]. In contrast, the only restriction activity so far identified against B-MLV is mediated by Fv1n, which allows viral DNA synthesis to proceed but inhibits viral nuclear import [28,29]. We thus infected MDTF cell lines expressing either wild-type or Y336A huTRIM5alpha, or control cells, with equal doses of N-, B- or Mo-MLV vectors and monitored the accumulation of reverse transcription products by PCR, using primers that amplified elongated minus-strand DNA (Figure 2B). All three vectors yielded readily detectable reverse transcripts in control cells at 6 hours post-infection. Consistent with previous studies, N-MLV DNA levels were significantly reduced in the presence of wild-type huTRIM5alpha, whereas B-MLV escaped this effect. In contrast, both N- and B-MLV exhibited strikingly reduced amounts of reverse transcripts in cells expressing huTRIM5alphaY336A. With Mo-MLV, a slight decrease in viral DNA was noted in cells expressing this mutant at 8 hours post-infection, compared with control or wild-type huTRIM5alpha-expressing cells. This inhibition was more obvious when the analysis was repeated at 5 days post-infection, that is, upon scoring the ultimate proviral load of the cells, which correlated with the results of the FACS analyses performed at the same time (Figure 2B and 2C). Altogether, these data indicate that wild-type and huTRIM5alphaY336A similarly act before the completion of reverse transcription.
###end p 21
###begin title 22
###xml 1 4 1 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
Y336 Exerts Negative Influence to Limit the Spectrum of huTRIM5alpha Antiviral Activity
###end title 22
###begin p 23
###xml 48 51 48 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 243 251 235 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g001">Figure 1</xref>
###xml 379 387 371 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g003">Figure 3</xref>
###xml 532 535 524 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 622 623 606 607 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 626 627 610 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</sub>
###xml 695 703 679 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g003">Figure 3</xref>
###xml 799 802 783 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 986 989 966 969 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 100 103 <span type="species:ncbi:11786">MLV</span>
###xml 257 260 <span type="species:ncbi:11786">MLV</span>
###xml 348 351 <span type="species:ncbi:11786">MLV</span>
###xml 667 670 <span type="species:ncbi:11786">MLV</span>
###xml 864 867 <span type="species:ncbi:11786">MLV</span>
###xml 896 899 <span type="species:ncbi:11786">MLV</span>
###xml 1072 1075 <span type="species:ncbi:11786">MLV</span>
###xml 1137 1142 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To explore further the modalities by which the Y336A mutation renders huTRIM5alpha active against B-MLV, we generated MDTF cell lines expressing huTRIM5alpha derivatives with other amino acid substitutions or with a deletion at this position (Figure 1B). N-MLV restriction was unaffected by any of these changes. In contrast, variable degrees of B-MLV restriction were observed (Figure 3). Introduction of other small amino acids besides alanine (threonine, serine, cysteine and, to a lesser extent, proline), or removal of tyrosine336, also conferred a gain-of-function phenotype to huTRIM5alpha. One mutant, huTRIM5alphaY336K, even acquired the ability to block Mo-MLV with a good efficiency (Figure 3). This did not simply reflect the presence of a positive charge at this position, because the Y336R mutation rendered huTRIM5alpha only weakly active against B-MLV and even less so against Mo-MLV, even though it might be due to its poor expression level. Notably, replacing tyrosine336 with glutamate or phenylalanine did not broaden huTRIM5alpha restriction beyond N-MLV. Moreover, none of the mutants acquired the ability to block HIV-1.
###end p 23
###begin title 24
###xml 51 54 47 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
Differential Restriction Spectrum of huTRIM5alpha Y336 Mutants
###end title 24
###begin p 25
###xml 75 83 71 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g001">Figure 1</xref>
###xml 127 130 <span type="species:ncbi:11786">MLV</span>
###xml 136 139 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
MDTF cells expressing indicated huTRIM5alpha derivatives, as documented in Figure 1B, were challenged with serial dilutions of MLV- and HIV-based GFP vectors, and analyzed by flow cytometry 2 days later. The resulting infectivity curves are representatives of at least two independent experiments.
###end p 25
###begin title 26
###xml 2 5 <span type="species:ncbi:11786">MLV</span>
###xml 42 47 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
B-MLV Restriction Seems Incompatible with HIV-1 Blockade
###end title 26
###begin p 27
###xml 179 181 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b024">24</xref>
###xml 182 184 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b025">25</xref>
###xml 185 187 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b030">30</xref>
###xml 582 584 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b024">24</xref>
###xml 585 587 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b025">25</xref>
###xml 588 590 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b030">30</xref>
###xml 593 601 585 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g004">Figure 4</xref>
###xml 705 708 697 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">332</sup>
###xml 711 714 703 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 798 801 790 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">332</sup>
###xml 804 807 796 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 810 818 802 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g004">Figure 4</xref>
###xml 824 825 816 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g004">4</xref>
###xml 971 979 963 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g004">Figure 4</xref>
###xml 985 986 977 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g004">4</xref>
###xml 1315 1316 1299 1300 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 1319 1320 1303 1304 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</sub>
###xml 1341 1349 1325 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g004">Figure 4</xref>
###xml 162 167 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 298 301 <span type="species:ncbi:11786">MLV</span>
###xml 312 317 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 556 559 <span type="species:ncbi:11786">MLV</span>
###xml 575 580 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 792 795 <span type="species:ncbi:11786">MLV</span>
###xml 895 898 <span type="species:ncbi:11786">MLV</span>
###xml 1105 1110 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1336 1339 <span type="species:ncbi:11786">MLV</span>
###xml 1422 1425 <span type="species:ncbi:11786">MLV</span>
###xml 1508 1513 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
It was previously demonstrated that a single amino acid substitution or deletion at position 332 of huTRIM5alpha provides this molecule with the ability to block HIV-1 infection [24,25,30]. We thus asked whether a molecule carrying changes at both positions 332 and 336 restricts not only N- and B-MLV, but also HIV-1. For this, we generated MDTF cell lines expressing a series of huTRIM5alpha double mutants, using various combinations of substitutions and deletions previously noted as broadening the spectrum of activity of the protein towards either B-MLV (this work) or HIV-1 [24,25,30] (Figure 4A). Double mutants that included an alanine substitution at position 336 were either poorly expressed (R332H/Y336A, data not shown) or expressed but without antiviral activity even against N-MLV (R332A/Y336A, Figure 4B and 4C). All other double mutants were stably expressed, and exhibited the MLV restriction patterns expected from the residue present at position 336 (Figure 4B and 4C). Single mutants with arginine to proline, histidine, alanine or a deletion at position 332 significantly restricted HIV-1, albeit it less efficiently than rhTRIM5alpha. However, none of the double mutants was effective against this virus. Furthermore, substitutions at position 332 somewhat reduced the ability of huTRIM5alphaY336K to restrict Mo-MLV (Figure 4C). It thus appears that changes underlying the acquisition of B- and Mo-MLV restriction ability preclude further extension of the activity of huTRIM5alpha to HIV-1.
###end p 27
###begin title 28
###xml 2 5 <span type="species:ncbi:11786">MLV</span>
###xml 10 13 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
B-MLV and HIV Restriction Are Mutually Exclusive
###end title 28
###begin p 29
(A) Single and double point mutations (*) were introduced at positions 332 and 336 in the V1 region of huTRIM5alpha as illustrated.
###end p 29
###begin p 30
###xml 141 149 141 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g001">Figure 1</xref>
(B) MDTF cell lines stably expressing these mutants were engineered by retroviral transduction, and analyzed by western blot as described in Figure 1.
###end p 30
###begin p 31
###xml 185 193 185 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g002">Figure 2</xref>
###xml 66 69 <span type="species:ncbi:11786">MLV</span>
###xml 73 76 <span type="species:ncbi:11786">MLV</span>
###xml 81 84 <span type="species:ncbi:11786">MLV</span>
###xml 88 91 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(C) These cells were challenged with 2-fold dilutions of either N-MLV, B-MLV, Mo-MLV or HIV-derived GFP-expressing vectors, and infections were scored by flow cytometry as described in Figure 2. Plots are representative of at least two independent experiments.
###end p 31
###begin title 32
###xml 48 51 <span type="species:ncbi:11786">MLV</span>
Context-Limited Influence of Residue 110 of the MLV Capsid on Susceptibility to huTRIM5alpha-Mediated Restriction
###end title 32
###begin p 33
###xml 181 182 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
###xml 190 191 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 239 240 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b004">4</xref>
###xml 241 242 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b005">5</xref>
###xml 243 245 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b027">27</xref>
###xml 465 467 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b027">27</xref>
###xml 468 470 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b031">31</xref>
###xml 471 473 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b032">32</xref>
###xml 736 737 720 721 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 740 741 724 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 833 841 817 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g005">Figure 5</xref>
###xml 1093 1096 1069 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">110</sup>
###xml 1220 1221 1192 1193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 1224 1225 1196 1197 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</sub>
###xml 1242 1243 1210 1211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 1246 1247 1214 1215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 1350 1352 1314 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b033">33</xref>
###xml 1355 1363 1319 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g005">Figure 5</xref>
###xml 40 43 <span type="species:ncbi:11786">MLV</span>
###xml 138 141 <span type="species:ncbi:11786">MLV</span>
###xml 319 322 <span type="species:ncbi:11786">MLV</span>
###xml 672 675 <span type="species:ncbi:11786">MLV</span>
###xml 780 783 <span type="species:ncbi:11786">MLV</span>
###xml 965 968 <span type="species:ncbi:11786">MLV</span>
###xml 1015 1018 <span type="species:ncbi:11786">MLV</span>
###xml 1189 1192 <span type="species:ncbi:11786">MLV</span>
The effective blockade of both N- and B-MLV by several huTRIM5alpha mutants strongly suggested that the "canonical" amino acid 110 of the MLV capsid, the importance of which for Fv1n and Fv1b sensitivity has been extensively demonstrated [4,5,27], did not play an essential role in the case of TRIM5alpha. The N- and B-MLV packaging constructs sequence used in the present study encode for viral capsids that differ in only three residues (CA109, CA110 and CA159) [27,31,32]. Exchanging the residue present in either virus at position 110, through reciprocal arginine-glutamate exchanges, sufficed to confer wild-type huTRIM5alpha susceptibility or resistance to N- and B-MLV. However, both mutants were potently blocked by huTRIM5alphaY336A, which also restricted either N- or B-MLV modified to contain an alanine at this position (Figure 5A). These data confirmed that TRIM5alpha can be altered to act in a CA110-independent manner. However, in the context of Mo-MLV, this capsid residue plays a pivotal role. Mo-MLV could indeed escape all forms of TRIM5alpha-mediated blockade when alanine110 of its capsid was changed to glutamate. Inversely, when arginine was introduced instead, Mo-MLV restriction by huTRIM5alphaY336K and huTRIM5alphaY336A was strengthened, and the virus became slightly sensitive to wild-type TRIM5alpha, as recently noted [33] (Figure 5B).
###end p 33
###begin title 34
###xml 30 33 <span type="species:ncbi:11786">MLV</span>
Context-Specific Influence of MLV Capsid Residue 110
###end title 34
###begin p 35
###xml 264 272 260 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g002">Figure 2</xref>
###xml 141 144 <span type="species:ncbi:11786">MLV</span>
MDTF cells stably expressing wild-type or mutant versions of huTRIM5alpha, or containing a control vector, were challenged with N-, B- or Mo-MLV-derived vectors packaged with wild-type or CA110-mutated capsids, as indicated. Infections were scored as described in Figure 2.
###end p 35
###begin title 36
###xml 54 57 <span type="species:ncbi:11786">MLV</span>
CA82, CA109, CA110, and CA117 Interdependently Affect MLV Sensitivity to huTRIM5alpha
###end title 36
###begin p 37
###xml 287 295 279 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g006">Figure 6</xref>
###xml 299 301 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b034">34</xref>
###xml 302 304 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b035">35</xref>
###xml 442 443 430 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 446 447 434 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 461 469 449 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g006">Figure 6</xref>
###xml 623 624 611 612 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 627 628 615 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 651 659 639 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g006">Figure 6</xref>
###xml 777 778 761 762 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 781 782 765 766 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</sub>
###xml 784 793 768 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g003">Figures 3</xref>
###xml 798 799 782 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g005">5</xref>
###xml 1068 1076 1048 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g007">Figure 7</xref>
###xml 63 66 <span type="species:ncbi:11786">MLV</span>
###xml 164 167 <span type="species:ncbi:11786">MLV</span>
###xml 188 191 <span type="species:ncbi:11786">MLV</span>
###xml 405 408 <span type="species:ncbi:11786">MLV</span>
###xml 576 579 <span type="species:ncbi:11786">MLV</span>
###xml 740 743 <span type="species:ncbi:11786">MLV</span>
###xml 889 892 <span type="species:ncbi:11786">MLV</span>
We then sought to define which other capsid residues influence MLV susceptibility to huTRIM5alpha-mediated blockade. For this, we focused on amino acids in N- or B-MLV that differ from Mo-MLV, and on positions previously demonstrated to influence restriction by huTRIM5alpha and/or Fv1 (Figure 6A) [34,35]. We found that single point mutations at positions 82 (N to D) or 117 (L to H) of capsid allowed B-MLV to escape completely huTRIM5alphaY336A restriction (Figure 6B). Nevertheless, the influence of these two mutations was context-dependent, because when introduced in N-MLV they relieved neither wild-type nor huTRIMaY336A-mediated restriction (Figure 6B). Furthermore, the newly introduced residues are those naturally present in Mo-MLV, which is blocked by huTRIM5alphaY336K (Figures 3 and 5B). The testing of a high number of additional single and combined mutants confirmed that MLV susceptibility to TRIM5alpha-mediated restriction is dictated by the interdependent influences of capsid residues 82, 109, 110 and 117 with a minor modulation by residue 159 (Figure 7).
###end p 37
###begin title 38
###xml 0 3 <span type="species:ncbi:11786">MLV</span>
MLV CA82 and CA117 Can Interfere with TRIM5alpha-Mediated Restriction
###end title 38
###begin p 39
###xml 53 56 <span type="species:ncbi:11786">MLV</span>
###xml 98 101 <span type="species:ncbi:11786">MLV</span>
###xml 108 111 <span type="species:ncbi:11786">MLV</span>
###xml 121 124 <span type="species:ncbi:11786">MLV</span>
###xml 264 267 <span type="species:ncbi:11786">MLV</span>
(A) Amino acids sequence alignments of Mo-, N- and B-MLV capsids. Residues that differ between Mo-MLV and N-MLV and/or B-MLV are highlighted in grey. The residues in italics at positions 109, 110 and 159 represent the only amino acids differences between N- and B-MLV capsids. Positions targeted by site-directed mutagenesis in the present study are indicated by an arrow.
###end p 39
###begin p 40
###xml 88 96 88 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g002">Figure 2</xref>
###xml 180 183 <span type="species:ncbi:11786">MLV</span>
(B) Infectivity assays with indicated cell lines and vectors, performed as described in Figure 2. Residues at positions 82 and 117 exert different influences whether in an N- or B-MLV context.
###end p 40
###begin title 41
###xml 63 66 <span type="species:ncbi:11786">MLV</span>
Susceptibility to huTRIM5alpha-Mediated Restriction of Various MLV Derivatives
###end title 41
###begin p 42
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 62 65 <span type="species:ncbi:11786">MLV</span>
###xml 95 98 <span type="species:ncbi:11786">MLV</span>
aIn addition to CA110, CA82, CA109, CA117, and CA159, Moloney MLV capsid differs from N- and B-MLV CA at eight other positions (CA4, CA46, CA147, CA202, CA214, CA229, CA242, CA244).
###end p 42
###begin p 43
Fold restriction: -, less than 2; (+), 2 to 5; +, 5 to 10; ++, more than 10 (calculated as described in Materials and Methods); ND: not done.
###end p 43
###begin p 44
The one-letter abbreviation of amino acids was used to designate residues present at CA110, CA82, CA109, CA117, and CA159 (A: alanine, D: aspartate, E: glutamate, G: glycine, H: histidine, L: leucine, N: asparagine, Q: glutamine, R: arginine, T: threonine).
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 206 208 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b013">13</xref>
###xml 209 211 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b017">17</xref>
###xml 212 214 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b018">18</xref>
###xml 215 217 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b024">24</xref>
###xml 218 220 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b027">27</xref>
###xml 368 371 <span type="species:ncbi:11786">MLV</span>
It is suspected, albeit not yet formally demonstrated, that TRIM5alpha-mediated retroviral restriction proceeds through the direct binding of the antiviral PRYSPRY domain to the capsid of incoming viruses [13,17,18,24,27]. The present study, which demonstrates that the consequences of mutations in the huTRIM5alpha PRYSPRY V1 can be counterbalanced by changes in the MLV capsid, and vice versa, lends strong credence to such a model.
###end p 46
###begin p 47
###xml 65 68 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 758 761 742 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 920 922 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b020">20</xref>
###xml 923 925 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b022">22</xref>
###xml 1040 1042 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b023">23</xref>
###xml 1068 1071 1048 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 1391 1394 1367 1370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 1546 1549 1518 1521 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">332</sup>
###xml 1653 1656 1617 1620 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mac</sub>
###xml 1658 1660 1622 1624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b030">30</xref>
###xml 2109 2112 2069 2072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 2195 2196 2155 2156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 2283 2286 2243 2246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">358</sup>
###xml 2293 2294 2253 2254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
###xml 2372 2374 2332 2334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b036">36</xref>
###xml 115 118 <span type="species:ncbi:11786">MLV</span>
###xml 166 169 <span type="species:ncbi:11786">MLV</span>
###xml 324 327 <span type="species:ncbi:11786">MLV</span>
###xml 389 392 <span type="species:ncbi:11786">MLV</span>
###xml 1483 1486 <span type="species:ncbi:11786">MLV</span>
###xml 1640 1645 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1959 1962 <span type="species:ncbi:11786">MLV</span>
###xml 1983 1988 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2246 2249 <span type="species:ncbi:11786">MLV</span>
###xml 2367 2370 <span type="species:ncbi:11786">MLV</span>
This work stands out by its identification of a residue, tyrosine336 of huTRIM5alpha, which limits the spectrum of MLV targets of this antiviral to the sole N-tropic MLV. A number of amino acid substitutions at this position, as well as a deletion of this residue, confer huTRIM5alpha with the additional ability to block B-MLV, and introduction of a lysine even expands restriction to Mo-MLV. Understanding fully the mechanism of this gain of function would require a determination of the tri-dimensional structure of the TRIM5alpha-capsid complex. In its absence, the crystal structures of the PRYSPRY domain of related proteins, PRYSPRY-19q13.4.1, GUSTAVUS and TRIM21, suggests that the V1 region of huTRIM5alpha could form a protruding loop with tyrosine336 situated underneath and in direct contact (at a less than 4 A distance) with residues in the V2 loop, which could limit the conformational flexibility of V1 [20-22]. However, the PRYSPRY V1 loops of TRIM5alpha and these other proteins differ in length, precluding firm analogy [23]. Alternatively, tyrosine336 may prevent the docking of V1 into its putative capsid-binding site by steric hindrance. This would be consistent with the finding that changes that most effectively broaden the spectrum of action of huTRIM5alpha are the removal of this tyrosine or its substitution by small amino acids. However, the observation that Y336K further expands the restriction spectrum of huTRIM5alpha not only to B- but also to Mo-MLV suggests that this model may be overly simplistic. Arginine332 of huTRIM5alpha was similarly found to interfere with ability of huTRIM5alpha to restrict HIV-1 and SIVmac [30]. In this case too, distinct amino acid changes differentially affected the strength with which either one of these two viruses was inhibited, suggesting that both positive and negative influences are at play. As well, our failure to generate a TRIM5alpha variant capable of blocking both N- and B-MLV on the one hand and HIV-1 on the other hand, by combining mutations at positions 332 and 336, points to more complex influences within V1 itself. cis-acting interferences have also been noted in Fv1, where the C-terminal part of Fv1b was shown to prevent this factor from blocking B-MLV, and where substitution of lysine358 of Fv1n by alanine could extend the restriction spectrum of this antiviral to N-MLV [36].
###end p 47
###begin p 48
###xml 480 483 468 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">110</sup>
###xml 756 758 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b037">37</xref>
###xml 815 818 799 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">110</sup>
###xml 859 862 843 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 1036 1037 1012 1013 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 1040 1041 1016 1017 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 1083 1084 1055 1056 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 1087 1088 1059 1060 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 1103 1104 1071 1072 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 1107 1108 1075 1076 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</sub>
###xml 1278 1281 1246 1249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">117</sup>
###xml 1287 1289 1255 1257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82</sup>
###xml 1404 1407 1368 1371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">336</sup>
###xml 133 136 <span type="species:ncbi:11786">MLV</span>
###xml 615 618 <span type="species:ncbi:11786">MLV</span>
###xml 951 954 <span type="species:ncbi:11786">MLV</span>
On the viral capsid side, our study indicates that at least four positions (CA82, CA109, CA110 and CA117) interdependently condition MLV susceptibility to huTRIM5alpha, whether in its wild-type or mutant forms. The influence of each of these four residues varies according to both the virus involved and the sequence of the TRIM5alpha PRYSPRY V1 region. Here, all viruses tested escaped wild-type huTRIM5alpha if they harbored a glutamic acid at position 110 of capsid. As such, E110 dominantly interfere with restriction. However, a recent study demonstrated that wild-type huTRIM5alpha could efficiently block an MLV retroviral vector packaged with a capsid derived from a primate endogenous retrovirus (PtERV) carrying a glutamic acid at this position [37]. As well, we found here that the protective effect of E110 could be abrogated by substitutions of Y336 in huTRIM5alpha, in which case CA82 and CA117 became determinant. Indeed, with N- and B-MLV-derived viruses, an aspartate at CA82 additionally allowed escape from TRIM5alphaY336A, and a histidine at CA117 from TRIM5alphaY336A and TRIM5alphaY336K. When CA110 was occupied by an arginine, the picture was completely reversed, as this residue dominantly potentiates susceptibility. Finally, with an alanine at CA110, H117 and D82 induced escape from wild-type TRIM5alpha, albeit in a CA109-dependent fashion, yet viruses remained sensitive to Y336-mutated forms of the restriction factor.
###end p 48
###begin p 49
###xml 551 552 551 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b033">33</xref>
###xml 264 267 <span type="species:ncbi:11786">MLV</span>
###xml 301 304 <span type="species:ncbi:11786">MLV</span>
###xml 580 583 <span type="species:ncbi:11786">MLV</span>
A picture is thus emerging from these data, whereby CA110 plays the role of primary determinant of restriction, with CA82, CA109 and CA117 acting as secondary modulators in a V1-conditioned fashion. However, the restriction pattern obtained with derivatives of Mo-MLV, which differs from the N- and B-MLV strains used here at nine CA positions besides these four, does not fully fit with this model, indicating its modulation by at least some of these other CA residues. Notably, a recent study demonstrated the importance of CA214 in potentiating Fv1n-mediated restriction of Mo-MLV only when CA110 was occupied by a glutamate [33].
###end p 49
###begin p 50
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b035">35</xref>
###xml 269 270 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 313 314 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</sub>
###xml 317 318 309 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 341 343 333 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82</sup>
###xml 414 415 402 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 417 419 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b035">35</xref>
###xml 440 441 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 444 445 428 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 564 565 548 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
###xml 567 569 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b035">35</xref>
###xml 0 3 <span type="species:ncbi:11786">MLV</span>
###xml 321 324 <span type="species:ncbi:11786">MLV</span>
###xml 469 472 <span type="species:ncbi:11786">MLV</span>
MLV CA82, CA109, CA110 and CA117 were also demonstrated to exert combinatorial influences on Fv1-mediated restriction [35]. In spite of this parallel, sequences leading to resistance or susceptibility to Fv1 and huTRIM5alpha are not identical. For instance, whereas Fv1b and huTRIM5alpha both potently restrict CAE110A B-MLV, an additional N82D mutation allows escape from huTRIM5alpha (this work) but not from Fv1b [35]. Also, huTRIM5alphaY336A-mediated blockade of B-MLV is relieved by change at CA117, which was previously shown not to affect restriction by Fv1n [35].
###end p 50
###begin p 51
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b038">38</xref>
###xml 125 133 125 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g008">Figure 8</xref>
###xml 323 331 316 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g008">Figure 8</xref>
###xml 1284 1286 1261 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b038">38</xref>
###xml 1781 1783 1750 1752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b038">38</xref>
###xml 1784 1786 1753 1755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b039">39</xref>
###xml 2222 2224 2183 2185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b040">40</xref>
###xml 2225 2227 2186 2188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b042">42</xref>
###xml 50 53 <span type="species:ncbi:11786">MLV</span>
###xml 576 579 <span type="species:ncbi:11786">MLV</span>
###xml 1561 1566 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1930 1935 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2041 2046 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2183 2186 <span type="species:ncbi:11786">MLV</span>
###xml 2191 2194 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The structure of the amino-terminal part of the N-MLV capsid in its hexameric state was resolved at a 2.5 A resolution [38] (Figure 8). A monomer consists of two-stranded beta-hairpins followed by six alpha helices. Interestingly, CA82, CA109, CA110 and CA117 are situated at the edge of a cavity formed by helices 4 to 6 (Figure 8). CA82 sits between helix 4 and 5 at the top of this pocket, across from CA109 and 110 on helix 6. CA117 is further down along the helix 6 side of the cavity. At least two scenarios can thus be envisioned for the binding of huTRIM5alpha to the MLV capsid. First, it might rely on the sum of individual interactions between TRIM5alpha residues, for instance in the PRYSPRY V1 loop, and capsid amino acids including 82, 109, 110 and 117. The non-essential nature of any of these four capsid positions for susceptibility or resistance to TRIM5alpha argues against this model, even though it is conceivable that the abrogation of some of these interactions might be compensated by the strengthening of others. In a second scenario, the TRIM5alpha-binding site would be located deeper in the pocket. This part of the protein is constituted by residues that are highly conserved, hence most probably play essential structural functions prohibiting mutation [38]. Escape could then be achieved by mounting obstacles to TRIM5alpha penetration into this pocket through changes at the more flexible yet critically placed CA82, CA109, CA110 and CA117 residues. By analogy, it is interesting to note that the cyclophilin-binding loop of the HIV-1 capsid, which has been postulated to interfere with the blockade of this virus by wild-type huTRIM5alpha, hangs over a very similar pocket formed by helices 4 to 7 of the structurally homologous lentiviral capsid [38,39]. As such, this loop, whether bound to or modified by cyclophilin A (CypA), could function as a lid to prevent huTRIM5alpha from accessing its HIV-1 CA binding site. However, recent data, which indicate that the positive effects of CypA binding to CA on HIV-1 replication do not depend upon the presence of huTRIM5alpha suggest that a strict parallel cannot be established between restriction of MLV and HIV by the cellular antiviral [40-42].
###end p 51
###begin title 52
###xml 72 75 <span type="species:ncbi:11786">MLV</span>
Highlighting of Functionally Critical Positions on the Structure of the MLV Capsid
###end title 52
###begin p 53
###xml 84 87 <span type="species:ncbi:11786">MLV</span>
Visualization of the previously defined structure of the N-terminal domain of the N-MLV capsid in its hexameric state, each monomer being given a different color. Secondary structures in one monomer with the six alpha helices (alpha1-6) and two beta-hairpins (beta1 and beta2) are represented in the lower right panel. The four residues at positions 82, 109, 110 and 117 are shown with their respective side chains. Atoms in the side chains are colored in grey for carbon, white for hydrogen, red for oxygen and blue for nitrogen. In the upper right panel, the molecular surface of the area framed in the red-colored monomer is enlarged and viewed in the orientation indicated by the arrow. Surfaces of the four residues at positions 82, 109, 110, and 117 are colored.
###end p 53
###begin title 54
Materials and Methods
###end title 54
###begin title 55
Cell lines and culture.
###end title 55
###begin p 56
###xml 0 9 0 9 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Mus dunni</named-content>
###xml 0 9 <span type="species:ncbi:254704">Mus dunni</span>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 244 248 <span type="species:ncbi:9913">calf</span>
Mus dunni tail fibroblasts (MDTFs) and human embryonic kidney 293T cells (HEK 293T) were purchased from the American Type Culture Collection (ATCC). All cell lines were cultivated in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum, 2 mM glutamine and antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin).
###end p 56
###begin title 57
Plasmids.
###end title 57
###begin p 58
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b032">32</xref>
###xml 383 392 383 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g002">Figures 2</xref>
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g003">3</xref>
###xml 412 420 412 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g004">Figure 4</xref>
###xml 448 457 448 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g002">Figures 2</xref>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g003">3</xref>
###xml 486 494 486 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g004">Figure 4</xref>
###xml 501 504 501 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">env</italic>
###xml 0 3 <span type="species:ncbi:11786">MLV</span>
###xml 80 83 <span type="species:ncbi:11786">MLV</span>
###xml 110 113 <span type="species:ncbi:11786">MLV</span>
###xml 242 245 <span type="species:ncbi:11786">MLV</span>
###xml 570 596 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
MLV-based particles were produced using packaging constructs containing Moloney MLV (pCIGPB), N- and B-tropic MLV CA (pCIG3-N and pCIG3-B) kindly provided by O. Danos and J. Stoye, respectively [32]. The GFP-encoding vector construct for all MLV reporter viruses was pCNCG kindly provided by R. Zufferey. Lentiviruses-based vectors were produced with the packaging construct psPAX2 (Figures 2A and 3) or pR8.74 (Figure 4) and the vector pWPTS-GFP (Figures 2A and 3) or pRRLsin PGK GFP (Figure 4). The env construct for all viral productions was pMD2G plasmid expressing vesicular stomatitis virus G protein. Many plasmids used are distributed by Addgene ().
###end p 58
###begin p 59
###xml 100 102 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b013">13</xref>
###xml 516 524 504 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0030200-st001">Table S1</xref>
###xml 4 7 <span type="species:ncbi:11786">MLV</span>
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 139 144 <span type="species:ncbi:9606">human</span>
###xml 252 255 <span type="species:ncbi:11786">MLV</span>
The MLV plasmid encoding human TRIM5alpha was a kind gift of J. Sodroski and was already described [13]. The amino acid coding sequence of human TRIM5alpha with a C-terminal epitope derived from influenza virus hemagglutinin (HA) was inserted in pLPCX MLV vector construct (Clontech) allowing for puromycin selection of transduced cells. Site-directed mutagenesis on pLPCX-huTRIM5alpha-HA, pCIG3-N, pCIG3-B and pCIGPB was performed with the XL QuickChange mutagenesis kit from Stratagene. Primers used are listed in Table S1. Proper site-directed mutagenesis was checked by sequencing reactions.
###end p 59
###begin title 60
Viral production.
###end title 60
###begin p 61
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 108 115 108 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag-pol</italic>
###xml 120 123 120 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">env</italic>
###xml 302 305 299 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">env</italic>
###xml 614 617 611 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fv1</italic>
All vector productions were performed by CaPO4-mediated transient co-transfection of the retroviral vector, gag-pol and env encoding constructs (; with some minor adjustments). Briefly, subconfluent HEK 293T cells were co-transfected with 21.5 mug of vectors, 14.6 mug packaging constructs and 7.9 mug env constructs in a 15-cm plate. Cells were washed 16 hours post-transfection and supernatants were harvested 12, 24 and 36 hours later. Recombinant retroviral vectors containing supernatants were centrifugated, filtrated, and in some cases were concentrated by ultracentrifugation. Titrations were performed on Fv1-null MDTF cells.
###end p 61
###begin title 62
Engineering of stable wild-type and mutant TRIM5alpha-expressing cell line.
###end title 62
###begin p 63
###xml 233 234 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 0 3 <span type="species:ncbi:11786">MLV</span>
###xml 68 73 <span type="species:ncbi:9606">human</span>
MLV-based retroviral vectors encoding wild-type or point mutants of human TRIM5alpha were produced using the pLPCX-derived plasmids as described above. Viral supernatants containing recombinant retroviral vectors were added on 5 x 104 MDTF cells. Forty-eight hours post-transduction, cells were expanded and selection for stably transduced cells was performed by adding puromycin (Sigma) at a concentration of 5 mug/ml. Cells were maintained continuously in the presence of puromycin.
###end p 63
###begin p 64
###xml 429 432 <span type="species:ncbi:10116">rat</span>
###xml 579 584 <span type="species:ncbi:10090">mouse</span>
###xml 654 659 <span type="species:ncbi:9940">sheep</span>
###xml 665 670 <span type="species:ncbi:10090">mouse</span>
###xml 694 705 <span type="species:ncbi:3704">horseradish</span>
To evaluate TRIM5alpha expression level, total proteins were extracted in a radioimmune precipitation assay buffer (phosphate-buffered-saline (PBS) with 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) supplemented with protease inhibitor cocktail (Calbiochem). Equal amounts of protein were resolved on a Tris-glycine SDS-Polyacrylamide gel followed by western blot. HA-tagged proteins were detected using peroxydase-conjugated rat monoclonal antibody (clone 3F10, Roche). Proliferating cell nuclear antigen (PCNA) was used as a protein loading control and was detected using a mouse monoclonal antibody (clone PC10, Calbiochem) followed by a secondary sheep anti-mouse antibody conjugated to horseradish peroxidase.
###end p 64
###begin title 65
Reverse transcript detection.
###end title 65
###begin p 66
###xml 65 66 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</sub>
###xml 69 70 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</sub>
###xml 159 160 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 286 287 277 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1160 1172 1143 1155 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Mus musculus</named-content>
###xml 195 198 <span type="species:ncbi:11786">MLV</span>
###xml 1160 1172 <span type="species:ncbi:10090">Mus musculus</span>
MDTF cells stably expressing wild-type huTRIM5alpha, huTRIM5alphaY336A or stably transduced with the empty pLPCX construct as a control were seeded at 2.5 x 104 in a 24-well plate. N-, B- and Mo-MLV viral stocks encoding GFP were treated with DNAse I (20 mug/ml) in the presence of MgCl2 (10 mM) for 30 minutes at 37degreesC. Cells were then transduced at an equal low multiplicity of infection. For all time points and for each cell line, a PCR negative control with azidothymidine (62.5 muM, Calbiochem) pre-treated cells was included. Cells were then harvested before transduction and 6 or 8 hours post-transduction. DNA was then extracted using the DNAeasy Tissue extraction kit from Quiagen. To detect the presence of provirus, cells were also collected 5 days post-transduction and processed for DNA extraction and FACS analysis. PCR reactions were performed using 5 mul of DNA extract. PCR amplified a region from the neomycin resistance gene (forward primer: 5' GCGTTGGCTACCCGTGATATTG 3') to the cytomegalovirus promoter (reverse primer: 5' TGGGCTATGAACTAATGACC 3') present in the intermediate reverse transcript resulting from RNA expressed by pCNCG. Mus musculus peripheral myelin protein (Pmp22, NM_008885) was used as a normalization gene (forward primer: 5' TTCGTCAGTCCCACAGTTTTCTC 3', reverse primer: 5' ACTCGCTAGTCCCAA GGGTCTA 3').
###end p 66
###begin title 67
Infection with GFP reporter vectors and calculation of the fold restriction.
###end title 67
###begin p 68
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
MDTF stable cell lines were seeded at 2.5 x 104 and transduced 24 hours later with 2-fold serial dilutions of GFP reporter vectors. Cells were harvested 48 hours post-transductions and fixed in 1% formaldehyde-containing PBS. The percentage of GFP-positive cells was determined by flow cytometry using the Beckton Dickinson FACScan or the multi-well plate reader Beckman Coulter Cell lab Quanta Flow Cytometer. Results were analysed with FlowJo 8.1.1 software.
###end p 68
###begin p 69
###xml 509 517 497 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030200-g007">Figure 7</xref>
###xml 51 54 <span type="species:ncbi:11786">MLV</span>
To calculate the fold restriction of the different MLV capsid mutants by huTRIM5alpha derivatives, a ratio was performed between the percentage of GFP-positive cells in the absence (cells stably transduced with the empty vector) and presence of huTRIM5alpha derivatives (cells stably expressing wild-type or mutants huTRIM5alpha). Ratios were calculated with each dose of GFP vector from at least two independent infections, and the average of these ratios was used for the semi-quantitative scoring given in Figure 7.
###end p 69
###begin title 70
Molecular imaging.
###end title 70
###begin p 71
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b038">38</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030200-b043">43</xref>
###xml 53 56 <span type="species:ncbi:11786">MLV</span>
The resolved structure of the N-terminal domain of N-MLV capsid in its hexameric state ([38]; PDB: 1U7K) was visualized using the UCSF Chimera software as described [43].
###end p 71
###begin title 72
Supporting Information
###end title 72
###begin title 73
Sequences of the Primers Used for the Site-Directed Mutagenesis
###end title 73
###begin p 74
Modified nucleotides to generate the specified amino acid substitution are highlighted in bold and are underlined. Site where nucleotides were removed to create amino acid deletion are indicated with "//".
###end p 74
###begin p 75
(29 KB XLS)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin title 77
Accession Numbers
###end title 77
###begin p 78
###xml 116 121 <span type="species:ncbi:9606">human</span>
The National Center for Biotechnology Information () accession numbers for the proteins discussed in this paper are human TRIM5alpha (AY625000), peripheral myelin protein Pmp22 (NM_008885), and Rhesus TRIM5alpha (AY523632).
###end p 78
###begin p 79
We thank Joseph Sodroski for the pLPCX-huTRIM5alpha-HA plasmid, Vincent Zoete and Olivier Michielin from the Protein Modeling Facility of the University of Lausanne for the molecular imagery, Marc Chambon and Nathalie Ballanfat from the EPFL Biomolecular Screening Facility for help with the multi-well FACS analyses, Sujana Nylakonda for technical assistance, and Isabelle Barde and Gisou van der Goot for advice on experiments and redaction of the manuscript.
###end p 79
###begin title 80
Abbreviations
###end title 80
###begin p 81
acquired immunodeficiency syndrome
###end p 81
###begin p 82
azidothymidine
###end p 82
###begin p 83
###xml 9 12 <span type="species:ncbi:11786">MLV</span>
B-tropic MLV
###end p 83
###begin p 84
capsid
###end p 84
###begin p 85
fluorescence-activated cell sorting
###end p 85
###begin p 86
Friend virus susceptibility 1
###end p 86
###begin p 87
green fluorescent protein
###end p 87
###begin p 88
hemagglutinin epitope
###end p 88
###begin p 89
###xml 0 5 <span type="species:ncbi:9606">human</span>
human
###end p 89
###begin p 90
###xml 0 35 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
human immunodeficiency virus type 1
###end p 90
###begin p 91
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mus dunni</italic>
###xml 0 9 <span type="species:ncbi:254704">Mus dunni</span>
Mus dunni tail fibroblast
###end p 91
###begin p 92
###xml 8 11 <span type="species:ncbi:11786">MLV</span>
Moloney MLV
###end p 92
###begin p 93
###xml 0 21 <span type="species:ncbi:11786">murine leukemia virus</span>
murine leukemia virus
###end p 93
###begin p 94
###xml 9 12 <span type="species:ncbi:11786">MLV</span>
N-tropic MLV
###end p 94
###begin p 95
phosphate-buffered saline
###end p 95
###begin p 96
proliferating cell nuclear antigen
###end p 96
###begin p 97
rhesus
###end p 97
###begin p 98
sodium dodecyl sulfate
###end p 98
###begin p 99
###xml 0 29 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
simian immunodeficiency virus of macaques
###end p 99
###begin p 100
tripartite motif 5alpha
###end p 100
###begin p 101
variable region
###end p 101
###begin title 102
References
###end title 102
###begin article-title 103
Intrinsic immunity: a front-line defense against viral attack
###end article-title 103
###begin article-title 104
###xml 58 62 <span type="species:ncbi:10090">mice</span>
Susceptibility to two strains of Friend leukemia virus in mice
###end article-title 104
###begin article-title 105
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
Positional cloning of the mouse retrovirus restriction gene Fv1
###end article-title 105
###begin article-title 106
###xml 70 93 <span type="species:ncbi:11786">murine leukemia viruses</span>
Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses
###end article-title 106
###begin article-title 107
###xml 33 54 <span type="species:ncbi:11786">murine leukemia virus</span>
Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance
###end article-title 107
###begin article-title 108
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha
###end article-title 108
###begin article-title 109
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 14 34 <span type="species:ncbi:9534">African green monkey</span>
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities
###end article-title 109
###begin article-title 110
###xml 52 75 <span type="species:ncbi:11786">murine leukemia viruses</span>
###xml 79 84 <span type="species:ncbi:9606">human</span>
TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells
###end article-title 110
###begin article-title 111
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 44 65 <span type="species:ncbi:11786">murine leukemia virus</span>
Trim5alpha protein restricts both HIV-1 and murine leukemia virus
###end article-title 111
###begin article-title 112
The tripartite motif family identifies cell compartments
###end article-title 112
###begin article-title 113
All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction
###end article-title 113
###begin article-title 114
Retrovirus restriction by TRIM5alpha variants from Old World and New World primates
###end article-title 114
###begin article-title 115
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys
###end article-title 115
###begin article-title 116
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity
###end article-title 116
###begin article-title 117
###xml 84 91 <span type="species:ncbi:8355">Xenopus</span>
Novel topology of a zinc-binding domain from a protein involved in regulating early Xenopus development
###end article-title 117
###begin article-title 118
A novel zinc finger coiled-coil domain in a family of nuclear proteins
###end article-title 118
###begin article-title 119
TRIM5alpha selectively binds a restriction-sensitive retroviral capsid
###end article-title 119
###begin article-title 120
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor
###end article-title 120
###begin article-title 121
Relationship between SPRY and B30.2 protein domains. Evolution of a component of immune defence?
###end article-title 121
###begin article-title 122
Structure of the PRYSPRY-domain: implications for autoinflammatory diseases
###end article-title 122
###begin article-title 123
Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function
###end article-title 123
###begin article-title 124
Structural and functional insights into the B30.2/SPRY domain
###end article-title 124
###begin article-title 125
The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates
###end article-title 125
###begin article-title 126
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction
###end article-title 126
###begin article-title 127
###xml 93 121 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction
###end article-title 127
###begin article-title 128
###xml 90 111 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 127 132 <span type="species:ncbi:9606">human</span>
Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha
###end article-title 128
###begin article-title 129
A conserved mechanism of retrovirus restriction in mammals
###end article-title 129
###begin article-title 130
###xml 20 41 <span type="species:ncbi:11786">murine leukemia virus</span>
Characterization of murine leukemia virus restriction in mammals
###end article-title 130
###begin article-title 131
###xml 100 121 <span type="species:ncbi:11786">murine leukemia virus</span>
Effect of Fv-1 gene product on synthesis of linear and supercoiled viral DNA in cells infected with murine leukemia virus
###end article-title 131
###begin article-title 132
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 56 84 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection
###end article-title 132
###begin article-title 133
###xml 116 139 <span type="species:ncbi:11786">murine leukemia viruses</span>
Nucleotide sequences of gag-pol regions that determine the Fv-1 host range property of BALB/c N-tropic and B-tropic murine leukemia viruses
###end article-title 133
###begin article-title 134
Use of a transient assay for studying the genetic determinants of Fv1 restriction
###end article-title 134
###begin article-title 135
###xml 32 61 <span type="species:ncbi:11801">Moloney murine leukemia virus</span>
Complex determinants within the Moloney murine leukemia virus capsid modulate susceptibility of the virus to Fv1 and Ref1-mediated restriction
###end article-title 135
###begin article-title 136
###xml 16 37 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
###xml 100 105 <span type="species:ncbi:9606">human</span>
Residues in the murine leukemia virus capsid that differentially govern resistance to mouse Fv1 and human Ref1 restrictions
###end article-title 136
###begin article-title 137
Retroviral capsid determinants of Fv1 NB and NR tropism
###end article-title 137
###begin article-title 138
###xml 51 72 <span type="species:ncbi:11786">murine leukemia virus</span>
Identification of the regions of Fv1 necessary for murine leukemia virus restriction
###end article-title 138
###begin article-title 139
###xml 44 49 <span type="species:ncbi:9606">human</span>
Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein
###end article-title 139
###begin article-title 140
High-resolution structure of a retroviral capsid hexameric amino-terminal domain
###end article-title 140
###begin article-title 141
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structure of the amino-terminal core domain of the HIV-1 capsid protein
###end article-title 141
###begin article-title 142
###xml 22 57 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity
###end article-title 142
###begin article-title 143
###xml 52 87 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 103 108 <span type="species:ncbi:9606">human</span>
Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells
###end article-title 143
###begin article-title 144
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1
###end article-title 144
###begin article-title 145
UCSF chimera-a visualization system for exploratory research and analysis
###end article-title 145
###begin p 146
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 22 25 <span type="species:ncbi:11263?0.47540983606557374|species:ncbi:12167?0.09016393442622951">PVM</span>
###xml 69 72 <span type="species:ncbi:11263?0.47540983606557374|species:ncbi:12167?0.09016393442622951">PVM</span>
###xml 164 167 <span type="species:ncbi:11263?0.47540983606557374|species:ncbi:12167?0.09016393442622951">PVM</span>
###xml 199 202 <span type="species:ncbi:11263?0.47540983606557374|species:ncbi:12167?0.09016393442622951">PVM</span>
Author contributions. PVM and DT conceived and designed experiments. PVM and SR performed the experiments. FS and DT contributed reagents/materials/analysis tools. PVM, PT, and DT analyzed the data. PVM and DT wrote the paper.
###end p 146
###begin p 147
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This study was supported by the Swiss National Science Foundation.
###end p 147
###begin p 148
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 148

